Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

Breast

Volumn 21, Issue 5, 2012, Pages 669-677

  Marinovich, M L ^a   Sardanelli, F ^b   Ciatto, S ^c   Mamounas, E ^d   Brennan, M ^a   Macaskill, P ^a   Irwig, L ^a   von Minckwitz, G ^e   Houssami, N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MILAN   (Italy)

^c APSS   (Italy)

^d Aultman Health Foundation   (United States)

^e GERMAN BREAST GROUP   (Germany)

Author keywords

Breast cancer; Magnetic resonance imaging; Neoadjuvant therapy; Patient monitoring; Sensitivity and specificity

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL EXAMINATION; COCHRANE LIBRARY; CONTRAST; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DRUG RESPONSE; DYNAMIC CONTRAST ENHANCED MRI; ECHOGRAPHY; EMBASE; FEMALE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TUMOR VOLUME;

EID: 84865987841     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.07.006     Document Type: Article

References (41)

1. Makhoul I., Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol 2011, 103(4):348-357.
2. Liu S.V., Melstrom L., Yao K., Russell C.A., Sener S.F. Neoadjuvant therapy for breast cancer. J Surg Oncol 2010, 101(4):283-291.
3. Kaufmann M., von Minckwitz G., Bear H.D., Buzdar A., Mcgale P., Bonnefoi H., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18(12):1927-1934.
4. Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006, 24(12):1940-1949.
5. Chollet P., Amat S., Cure H., De Latour M., Le Bouedec G., Mouret-Reynier M.A., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86(7):1041-1046.
6. Montagna E., Bagnardi V., Rotmensz N., Viale G., Pruneri G., Veronesi P., et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010, 124(3):689-699.
7. Smith I.C., Heys S.D., Hutcheon A.W., Miller I.D., Payne S., Gilbert F.J., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20(6):1456-1466.
8. Heys S.D., Hutcheon A.W., Sarkar T.K., Ogston K.N., Miller I.D., Payne S., et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002, 3(Suppl. 2):S69-S74.
9. von Minckwitz G., Blohmer J.U., Costa S.D., Denkert C., Eidtmann H., Eiermann W., et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients - results of the GeparTrio trial. Cancer Res 2011, 71(24 Suppl.):103s.
10. von Minckwitz G., Kummel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized gepartrio trial. J Natl Cancer Inst 2008, 100(8):542-551.
11. Arlinghaus L.R., Li X., Levy M., Smith D., Welch E.B., Gore J.C., et al. Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol 2010, 2010.
12. Sardanelli F., Boetes C., Borisch B., Decker T., Federico M., Gilbert F.J., et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010, 46(8):1296-1316.
13. Whiting P., Rutjes A.W.S., Reitsma J.B., Bossuyt P.M.M., Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:1-13.
14. Whiting P.F., Weswood M.E., Rutjes A.W.S., Reitsma J.B., Bossuyt P.N.M., Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006, 6.
15. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 2001, 30:96-102.
16. Corcioni B., Santilli L., Quercia S., Zamagni C., Santini D., Taffurelli M., et al. Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapy. J Ultrasound 2008, 11(4):143-150.
17. Padhani A.R., Hayes C., Assersohn L., Powles T., Makris A., Suckling J., et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006, 239(2):361-374.
18. Li S.P., Taylor N.J., Makris A., Ah-See M.L.W., Beresford M.J., Stirling J.J., et al. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology 2010, 257(3):643-652.
19. Baek H.M., Chen J.H., Nie K., Yu H.J., Bahri S., Mehta R.S., et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 2009, 251(3):653-662.
20. Loo C.E., Straver M.E., Rodenhuis S., Muller S.H., Wesseling J., Vrancken Peeters M.J., et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 2011 Feb 20, 29(6):660-666.
21. Carbonaro L.A., Pediconi F., Verardi N., Trimboli R.M., Calabrese M., Sardanelli F. Breast MRI using a high-relaxivity contrast agent: an overview. Am J Roentgenol 2011, 196(4):942-955.
22. Fangberget A., Nilsen L.B., Hole K.H., Holmen M.M., Engebraaten O., Naume B., et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 2011 Jun, 21(6):1188-1199.
23. Kim S.J., Taguchi T., Shimazu K., Tanji Y., Tamaki Y., Noguchi S. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide. Oncology 2009, 77(2):134-139.
24. Loo C.E., Teertstra H.J., Rodenhuis S., Van De Vijver M.J., Hannemann J., Muller S.H., et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. Am J Roentgenol 2008, 191(5):1331-1338.
25. Ah-See M.L.W., Makris A., Taylor N.J., Harrison M., Richman P.I., Burcombe R.J., et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008, 14(20):6580-6589.
26. Tozaki M., Sakamoto M., Oyama Y., Maruyama K., Fukuma E. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Im 2010 Apr, 31(4):895-902.
27. Martincich L., Montemurro F., De Rosa G., Marra V., Ponzone R., Cirillo S., et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Res Treat 2004, 83(1):67-76.
28. Jacobs M.A., Stearns V., Wolff A.C., Macura K., Argani P., Khouri N., et al. Multiparametric magnetic resonance imaging, spectroscopy and Multinuclear (23Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol 2010, 17(12):1477-1485.
29. Yu Y., Jiang Q., Miao Y., Li J., Bao S., Wang H., et al. Quantitative analysis of clinical dynamic contrast-enhanced MR imaging for evaluating treatment response in human breast cancer. Radiology 2010, 257(1):47-55.
30. Husband J.E., Schwartz L.H., Spencer J., Ollivier L., King D.M., Johnson R., et al. Evaluation of the response to treatment of solid tumours - a consensus statement of the International cancer imaging society. Br J Cancer 2004, 90(12):2256-2260.
31. Sargent D.J., Rubinstein L., Schwartz L., Dancey J.E., Gatsonis C., Dodd L.E., et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009, 45(2):290-299.
32. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47(1):207-214.
33. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
34. Thibault F., Nos C., Meunier M., El Khoury C., Ollivier L., Sigal-Zafrani B., et al. MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. Am J Roentgenol 2004, 183(4):1159-1168.
35. Esteva F.J., Hortobagyi G.N. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?. J Natl Cancer Inst 2008, 100(8):521-523.
36. Berg W.A., Madsen K.S., Schilling K., Tartar M., Pisano E.D., Larsen L.H., et al. Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology 2010, 258(1):59-72.
37. von Minckwitz G., Kaufmann M., Kuemmel S., Fasching P.A., Eiermann W., Blohmer J.U., et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol 2011, 29. (Suppl; abstr 1028).
38. Lord S.J., Irwig L., Simes R.J. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?. Ann Intern Med 2006, 144(11):850-855.
39. Kul S., Cansu A., Alhan E., Dinc H., Reis A., Can G. Contrast-enhanced MR angiography of the breast: evaluation of ipsilateral increased vascularity and adjacent vessel sign in the characterization of breast lesions. Am J Roentgenol 2010, 195(5):1250-1254.
40. Pickles M.D., Gibbs P., Lowry M., Turnbull L.W. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006, 24(7):843-847.
41. O'Flynn E.A.M., deSouza N.M. Functional magnetic resonance: biomarkers of response in breast cancer. Breast Cancer Res 2011, 13(1).